RHP 5.54MTRN 4.28PSMT 0ESLOY 0MSFT -8.48META -4.53HLPR.TO 0VDY.TO -0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

24.04
-0.68 (2.75%)
as of Jun 24, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges including a patent cliff and the aftermath of over-earning during the COVID-19 pandemic. The company has made efforts to bolster its drug pipeline through acquisitions, such as Seagen, but many experts express concerns about the lack of earnings momentum and blockbusters to drive growth. While the stock offers an attractive dividend yield (around 6-7%), there is a prevailing sentiment around its long-term growth prospects as reliance on cost-cutting and strategic acquisitions seems insufficient. Analysts highlight the need for a new growth catalyst, particularly in oncology, to reassure investors as the dividend yield may be at risk if substantial progress with new drugs is not achieved. Overall, patience is emphasized by many experts, with a hope that the stock will eventually perform better amid potential improvements in government policies and market conditions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
AstraZeneca, AZN
PAST TOP PICK

Pfizer Inc(PFE)

May 12, 2008
(A Top Pick May 18/07. Down 23%.) Have not proven to be defensive. Most of the major drug companies have more of their larger drugs coming off patent shortly. At this point, downside risk looks pretty limited. 6% plus yield. A Hold.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$19.91

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 08, 2008
(A Top Pick May 2/07. Down 20%.) Still in his Top 10. His model price is $34.72, a 74% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$19.97

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 25, 2008
The trouble he has with the big pharmaceuticals is that they are having a terribly hard time reinventing themselves. They all have good yields. The FDA right now is turning the taps off. It is harder and harder to get approval. Would be very cautious on this sector. The one exception is Johnson & Johnson (JNJ-N), which seems to have a better approach than their peers.
Photo of Duncan StewartDuncan Stewart
No
Unlock Rating
$20.43

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 23, 2008
This has not been a good experience over the last year. Stock has come off pretty sharply. All of the drugs are coming off patent for the big pharmaceuticals. Trading at under 10X earnings and is still earning 35% on its equity and yielding over 6%.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$19.88

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 15, 2008
US pharmaceutical sector is under tremendous pressure. Starting to see a run off in many of the product portfolios and a wind down of patent protection. With the potential change of government he expects the whole sector will be under pressure.
Photo of Alan Kral , CFA, CICAlan Kral , CFA, CIC
No
Unlock Rating
$20.71

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 10, 2008
Good stock to own in a bad market. 6% yield. $25 billion in cash. The bad news is known including some of the big drugs coming off of patent and the lull before some of their late stage pipe line starts to kick in.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$20.92

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 07, 2008
This is a difficult one for a value investor. The stock is down quite a bit and has a great balance sheet with a lot of cash. However, this could be a value trap. Looking forward, this company is going to be losing a lot of its primary drugs. Also, there is an election coming up and the rules may change on drug pricing.
Photo of Pat NaccaratoPat NaccaratoUnlock Rating
$21.48

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 25, 2008
Dividend over 6%. Would hold for the dividend. Wouldn’t buy.
Photo of Benj GallanderBenj GallanderUnlock Rating
$20.78

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
HOLD

Pfizer Inc(PFE)

Mar 17, 2008
They’ve got lots of cash, therefore their dividend is safe. Not sure if they are going to be able to build their business to have significant growth.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$20.57

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 06, 2008
Pretty cheap. Has been a dog over the last year but you are getting a 5.5% dividend. PE is 11X’s. Their patent on the Lipitor drug expires, but not for another 12 years. Cash flow from this is about 40% of their profit and they are moving into other new drugs. If the Democrats win, the question is will they get squeezed on Medicare but that is already built into the stock.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$21.59

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 06, 2008
Trading at 10X earnings, which is the lowest he has ever seen a US pharmaceutical. They are great beneficiaries of the lower US$. Have a great international business. Have lots of cash for acquisitions.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$21.59

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 03, 2008
(Market Call Minute.) At this price, you can be a buyer and sell at $26 or so.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$22.25

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 27, 2008
He has a model price of $40.10, which is a 76% positive differential. Has up its dividends considerably and has positive earnings revisions.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.75

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 20, 2008
Their pipeline has just not produced new drugs. When you buy this stock now, you are getting a series of cash flows on the existing drugs, but a lot of them are coming off patent. Just acquired a company that has a very small drug, which to him, is a sign of desperation.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$22.47

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 19, 2008
This is the worst of times for giant pharmaceutical companies. Now spending more on marketing than they are on research/development. Ongoing huge costs of developing new drugs that are safe are a drag. Also, cost of litigation remains a huge burden. Probably safer with the generic companies.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$22.37

Stock price when the opinion was issued

$24.04

As of Jun 24, 2026. Market Open.

biotechnologypharmaceutical
Showing 526 to 540 of 883 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

MSFT -8.48$365.46
PPL.TO -0.83$66.15
CVE.TO -1.49$35.09
TOU.TO -0.68$59.86
GOOG -1.04$345.04

Today's Top Picks

RHP 5.54$129.77
MTRN 4.28$269.62
PSMT 0$
ESLOY 0$95.66
MSFT -8.48$365.46

Popular Articles

Latest Sell Signals

ATD.TO 1.89$93.76
ITB 5.99$103.32
GLD -11.4$365.92
MU -3.26$1048.51
MU -3.26$1048.51

Most Recent Experts

Brendan Caldwell

Brendan Caldwell

Caldwell Securities

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica